Table 1

Clinical features of the participants who contributed plasma

Characteristics

RA

OA

HC


Number of participants

30

30

30

Sex, male/female

8/22

7/23

13/17

Age, mean (range)

60.1 (22 to 77)

75.1 (65 to 89)

46.5 (32 to 62)

Disease duration (y), mean (range)

10.4 (0.3 to 32)

NA

NA

Positive anti-CCP antibody, n (%)

10 (90.9%)

NA

NA

ESR (mm), mean (range)

37.2 (4 to 116)

NA

NA

CRP (mg/dl), mean (range)

2.1 (0 to 9.6)

NA

NA

MMP3 (ng/ml), mean (range)

290.1 (32.4 to 800)

NA

NA

DAS28, mean (range)

4.4 (1.7 to 7.1)

NA

NA

SJC, mean (range)

4.3 (0 to 13)

NA

NA

TJC, mean (range)

4.5 (0 to 27)

NA

NA

VAS

42.3 (0 to 95)

NA

NA

Steinbrocker Stage, n

I: 4, II: 3, III: 6, IV: 17

NA

NA

Steinbrocker Class, n

I: 1, II: 24, III: 5, IV: 0

NA

NA

Kellgren/Lawrence grade, n

NA

I: 0, II: 0, III: 9, IV: 21

NA

Medication, n (%)

Prednisolone

21 (70%)

NA

NA

Methotrexate

18 (60%)

NA

NA

Infliximab

8 (27%)

NA

NA

Eternercept

2 (6.7%)

NA

NA

Tocilizumab

2 (6.7%)

NA

NA

Tacrolimus

2 (6.7%)

NA

NA

Salazosulfapyridine

6 (20%)

NA

NA

Bucillamine

5 (17%)

NA

NA

Mizoribine

0 (0%)

NA

NA

Gold

1 (3.3%)

NA

NA


CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; HC, healthy control; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale of general health;

† anti-CCP antibodies of 10 patients were positive among 11 patients examined.

Murata et al. Arthritis Research & Therapy 2010 12:R86   doi:10.1186/ar3013

Open Data